Advantech and Vivo back Sinovac R&D's development of COVID-19 vaccine
Advantech Capital and Vivo Capital has invested $15 million in Sinovac R&D to accelerate development of a COVID-19 vaccine.
22 May 2020•3 mins read
Advantech Capital and Vivo Capital has invested $15 million in Sinovac R&D to accelerate development of a COVID-19 vaccine.
Francisco Partners completes $650m take-private of healthcare software firm Weave
2 hours ago · 2 mins read
Falfurrias-backed Edge Industrial Technologies buys blade resharpener Harvest Blade
4 hours ago · 1 min read
5th Century Partners sells Radon Medical Imaging to Leonard Green
4 hours ago · 1 min read
Virent Capital strikes deal to back higher education marketing agency Kanahoma
4 hours ago · 2 mins read
Truelink Capital agrees to carve-out of Johnson Controls’ global intrusion products business
6 hours ago · 2 mins read
Victor Capital-backed Adventure Ready Brands buys waterless hygiene maker CleanLife
6 hours ago · 1 min read
Eurazeo’s Christophe Bavière: Diversifying Europe’s mid-market
8 hours ago · 7 mins read
